Literature DB >> 18471163

Pneumocystis jiroveci pneumonia in a patient with Wegener's granulomatosis treated efficiently with caspofungin.

Herbert Hof1, Peter Schnülle.   

Abstract

A patient with Wegener's granulomatosis was on steroids (20 mg prednisolone per day) when he fell ill with an atypical pneumonia caused by Pneumocystis, which was diagnosed by detection of antigen in repeated bronchial lavage specimens. Because other treatment options were contraindicated, he received intravenous caspofungin starting with a loading dose of 70 mg and a maintenance dose of 50 mg daily over 3 weeks thereafter. The patient's complaints subsequently resolved within days after initiation of treatment. Tolerability of the drug was excellent. No relapse occurred during the ongoing 4 years, although immunosuppressive therapy continued.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18471163     DOI: 10.1111/j.1439-0507.2008.01530.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  11 in total

Review 1.  Update on the diagnosis and treatment of Pneumocystis pneumonia.

Authors:  Eva M Carmona; Andrew H Limper
Journal:  Ther Adv Respir Dis       Date:  2010-08-24       Impact factor: 4.031

2.  Susceptibility of Pneumocystis to echinocandins in suspension and biofilm cultures.

Authors:  Melanie T Cushion; Margaret S Collins
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

3.  Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection.

Authors:  Melanie T Cushion; Michael J Linke; Alan Ashbaugh; Tom Sesterhenn; Margaret S Collins; Keeley Lynch; Ronald Brubaker; Peter D Walzer
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

4.  Echinocandins for Pneumocystis jirovecii pneumonia in non-HIV patients: A case report.

Authors:  Hui-Bin Huang; Jing-Min Peng; Bin Du
Journal:  Exp Ther Med       Date:  2018-08-07       Impact factor: 2.447

5.  Site-Directed Mutagenesis of the 1,3-β-Glucan Synthase Catalytic Subunit of Pneumocystis jirovecii and Susceptibility Assays Suggest Its Sensitivity to Caspofungin.

Authors:  A Luraschi; S Richard; P M Hauser
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

6.  Granulomatosis with polyangitis with mononeuritis multiplex-immunosuppressives playing a double-edged sword.

Authors:  Subhasis Mukherjee; Debabani Biswas; Shabana Begum; Pulakesh Bhanja; Amartya Kumar Misra; Partha Chatterjee
Journal:  Lung India       Date:  2014-10

7.  Efficacy of caspofungin combined with clindamycin for Pneumocystis jirovecii pneumonia in a systemic lupus erythematosus patient: A case report and literature review.

Authors:  Di-Hong Yang; Yuan Xu; Lu Hong; Zhou-Ye Song; Wei-Hong Ge
Journal:  Respir Med Case Rep       Date:  2018-12-08

8.  Treatment of Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus-infected patients using a combination of trimethoprim-sulfamethoxazole and caspofungin.

Authors:  Huan-Huan Wu; Shuang-Yan Fang; Yan-Xiao Chen; Lan-Fang Feng
Journal:  World J Clin Cases       Date:  2022-03-26       Impact factor: 1.337

9.  Non-HIV-infected patients with Pneumocystis pneumonia in the intensive care unit: A bicentric, retrospective study focused on predictive factors of in-hospital mortality.

Authors:  Yuqiong Wang; Xu Huang; Ting Sun; Guohui Fan; Qingyuan Zhan; Li Weng
Journal:  Clin Respir J       Date:  2022-01-10       Impact factor: 1.761

Review 10.  Natural Antimicrobial Peptides as Inspiration for Design of a New Generation Antifungal Compounds.

Authors:  Małgorzata Bondaryk; Monika Staniszewska; Paulina Zielińska; Zofia Urbańczyk-Lipkowska
Journal:  J Fungi (Basel)       Date:  2017-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.